Maria Jimena Salgueiro

Dr. Maria Jimena Salgueiro


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Nutrition
Verified
Journal Article
Closed access
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
MZMarcela B. Zubillaga
Marcela B. Zubillaga
ALAlexis E. Lysionek
Alexis E. Lysionek
RCRicardo A. Caro
Ricardo A. Caro
RWRicardo Weill
Ricardo Weill
JBJosé R. Boccio
José R. Boccio

3 October 2025 in Journal of Nanotheranostics
Verified
Journal Article
Open access
PDF file
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
MZMarcela Beatriz Zubillaga
Marcela Beatriz Zubillaga
The convergence of nanotechnology with nuclear medicine has led to the development of theranostic nanoplatforms that combine targeted imaging and therapy within a single system. This review provides a critical and updated synthesis of the current state of nanoplatform-based theranostics, with a particular focus on their application in oncology. We explore multifunctional nanocarriers that integrate diagnostic radionuclides for SPECT/PET imaging with therapeutic radioisotopes (α-, β-, or Auger emitters), chemotherapeutics, and biological targeting ligands. We highlight advances in nanomaterial engineering—such as hybrid architectures, surface functionalization, and stimuli-responsive designs—that improve tumor targeting, biodistribution, and therapeutic outcomes. Emphasis is placed on translational challenges including pharmacokinetics, toxicity, regulatory pathways, and GMP-compliant manufacturing. The article closes with a forward-looking perspective on how theranostic nanoplatforms could reshape the future of personalized oncology through precision-targeted diagnostics and radiotherapy.

1 February 2008 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
HDHebe Duran
Hebe Duran
MPMonica Palmieri
Monica Palmieri
RPRosana Pirchio
Rosana Pirchio
VMVanina A Medina
Vanina A Medina
MZMarcela Zubillaga
Marcela Zubillaga

1 March 2008 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
HDH. Durán
H. Durán
MPM. Palmieri
M. Palmieri
RPR. Pirchio
R. Pirchio
JNJ. Nicolini
J. Nicolini
MZM. Zubillaga
M. Zubillaga

1 September 2000 in Nutrition
Verified
Journal Article
Closed access
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
MZMarcela B Zubillaga
Marcela B Zubillaga
ALAlexis E Lysionek
Alexis E Lysionek
MSMarı́a I Sarabia
Marı́a I Sarabia
RCRicardo A Caro
Ricardo A Caro
JBJosé R Boccio
José R Boccio

3 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VGVirna Margarita Martín Giménez
Virna Margarita Martín Giménez
MMMarcela Analía Moretton
Marcela Analía Moretton
DCDiego Andrés Chiappetta
Diego Andrés Chiappetta
MSMaria Jimena Salgueiro
Maria Jimena Salgueiro
Miguel Walter FornesMiguel Walter Fornes
Miguel Walter Fornes
Walter ManuchaWalter Manucha
Walter Manucha
We have previously demonstrated significant in vitro natriuretic effects of anandamide (AEA) nanoformulation in polymeric nanoparticles, whose size prevents their accumulation in organs, such as the kidneys. Therefore, it is of particular interest to design and test nanostructures that can pharmacologically accumulate in these organs. In this regard, we prepared and characterized polymeric nanomicelles (~14 and 40 nm). Likewise, their biodistribution was determined. Spontaneously hypertensive rats (SHR) and normotensive rats (WKY), n = 3 per group, were divided into five treatment conditions: control, sham, free AEA freshly dispersed in aqueous solution or 24 h after its dispersion, and AEA encapsulated in nanomicelles. The kidneys were the main site of accumulation of the nanoformulation after 24 h. Freshly dispersed free AEA showed its classical triphasic response in SHR, which was absent from all other treatments. Nanoformulated AEA produced a sustained antihypertensive effect over 2 h, accompanied by a significant increase in fractional sodium excretion (FSE %). These effects were not observed in WKY, sham, or free AEA-treated rats after 24 h of its aqueous dispersion. Without precedent, we demonstrate in vivo natriuretic, diuretic, and hypotensive effects of AEA nanoformulation in polymeric nanomicelles, suggesting its possible use as a new antihypertensive agent with intravenous administration and passive renal accumulation.